NINDS Technology Transfer Office NINDS Technology Transfer Office NINDS Technology Transfer Office
Link to NINDS Home Site NINDS TTO Home Page Link to Neuroscience@NIH TTO Forms
About NINDS TTO
For Investigators
For Industry
Available Collaborations and Licenses
Useful Links

Collaboration Opportunities
NINDS Licensing Opportunities

Ongoing NINDS Clinical Trials


Search Licensing
 
Research and Technology Review
 
Licensing Opportunity  (full list)
 
Compositions and Methods for Diagnosis and Treatment of Chemotherapy-Resistant Neoplastic Disease
 
Institute : National Institute of Neurological Disorders and Stroke (NINDS)
 
Description of Invention :

The present invention relates to compositions and methods for the treatment of a neoplastic disease state (i.e. tumors) using RNA interference-mediated down regulation of stathmin expression. This invention also discloses methods for determining the presence or predisposition to a neoplastic disease state.
Stathmin is a cytoplasmic protein that is highly expressed in many different types of tumors such as leukemias, lung cancers and brain tumors.

Stathmin is believed to be involved in the regulation of the cell cycle via its interactions with microtubules. Lowering the expression of stathmin in tumor cells using RNA interference (RNAi) technology causes a decrease in tumor cell growth and also causes such cells to become more sensitive to the effects of standard chemotherapeutic agents.

Accordingly, the delivery of stathmin RNAi oligonucleotides either alone or in combination with standard chemotherapies may be used to treat patients with various tumors. For example, retroviruses or adeno-associated viruses containing stathmin RNAi oligonucleotides could be delivered to brain tumors in order to decrease cell growth and increase sensitivity to standard chemotherapies.
 
Inventors :

John Park (NINDS)
 
Patent Status :

U.S. Provisional Application No. 60/571,296 filed 15 May 2004
PCT Application No. PCT/US2005/016924 filed 13 May 2005 ; Published as WO 2005/12050 on December 22, 200f.
 
NIH Reference Number:
E-192-2004/0
 
Portfolios :
Cancer -Diagnostics
Cancer -Therapeutics
 
For Additional Information Please Contact:
Jasbir (Jesse) S. Kindra J.D., NIH Office of Technology Transfer
Phone: (301) 435-5559 Email: kindraj@mail.nih.gov
 
For Additional Information Regarding Collaboration with the Investigator Please Contact:
Laurie Arrants, Technology Development Administrator
Phone: 301-435-3112 Email: arrantsL@ninds.nih.gov
 
 
Last Updated: 7/20/2006
 
Contact us at nindstto@ninds.nih.gov
NINDS Home   |  NINDS TTO Home  | NeuroScience@NIH  |   Forms
DHHS   |  NIH  | FirstGov  |   Accessibility |   Privacy   | Site Index